XML 24 R15.htm IDEA: XBRL DOCUMENT
v3.21.2

Note 9 - Stockholders' Equity | 6 Months Ended
--- | ---
Jun. 30, 2021
Notes to Financial Statements |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 9 — STOCKHOLDERS’ EQUITY Public Offering and Private Placement In the second quarter of 2020, the Company completed two public offerings. In April 2020, a Common Stock offering generating gross proceeds of approximately $5.1 million (5,420,000 common shares and 2,710,000 warrants). The combined price of the shares and warrants was $0.95 per share. The warrants are exercisable at a price of $1.20 per share and have an expiration of three years from the issue date. In June 2020, the Company completed a second Common Stock offering generating gross proceeds of approximately $14.6 million (6,770,000 common shares and 3,749,000 warrants). The combined price of the shares and warrants was $2.15 per share. The warrants are exercisable at $2.60 and expire three years from the issue date. Warrants The following table summarizes information about shares issuable under warrants outstanding as of June 30, 2021 :
|  | Warrant shares outstanding |  |  | Weighted Average exercise price |  |  | Weighted Average remaining life |  |  | Intrinsic value |
Outstanding at January 1, 2021 |  |  | 6,369,396 |  |  | $ | 1.97 |  |  | $ | 2.48 |  |  | $ | 2,784,117 |
Issued |  |  | - |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  | (2,004,926 | ) |  |  | 1.57 |  |  |  | - |  |  |  |  |
Expired or cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding and exercisable at June 30, 2021 |  |  | 4,364,470 |  |  | $ | 2.15 |  |  | $ | 2.01 |  |  | $ | 1,796,413 |
The following table summarizes information about shares issuable under warrants outstanding as of June 30, 2020
|  | Warrant shares outstanding |  |  | Weighted Average exercise price |  |  | Weighted Average remaining life |  |  | Intrinsic value |
Outstanding at January 1, 2020 |  |  | 1,074,171 |  |  | $ | 0.50 |  |  | $ | 4.10 |  |  | $ | 956,012 |
Issued |  |  | 6,459,000 |  |  |  | 2.01 |  |  |  | 3.00 |  |  |  | - |
Exercised |  |  | (1,081,475 | ) |  |  | 0.88 |  |  |  | - |  |  |  | - |
Expired or cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding and exercisable at June 30, 2020 |  |  | 6,451,696 |  |  | $ | 1.95 |  |  | $ | 2.98 |  |  | $ | 2,430,184 |
Shares to Be Issued As of June 30, 2021 and 2020, there were 2,264,127 and 2,370,345 shares to be issued whose issuance has been deferred to the certain executives and employees of Milestone Scientific, respectively. As of June 30, 2021 and 2020, there were 144,024 and 149,285 shares, respectively, to be issued to non-employees, that will be issued for services rendered. The number of shares was fixed at the date of grant and were fully vested upon grant date. The following table summarizes information about shares to be issued on June 30, 2021 and 2020, respectively.
|  | June 30, 2021 |  |  | June 30, 2020 |
Shares-to-be-issued, outstanding January 1, 2021 and 2020, respectively |  |  | 2,428,329 |  |  |  | 2,375,760 |
Granted in current period |  |  | 33,238 |  |  |  | 358,482 |
Issued in current period |  |  | (53,416 | ) |  |  | (214,612 | )
Shares-to be issued outstanding June 30, 2021 and 2020, respectively |  |  | 2,408,151 |  |  |  | 2,519,630 |
Stock Option Plans In June 2011, the stockholders of Milestone Scientific approved the 2011 Stock Option Plan (the "2011 Plan") which originally provided for stock options to our employees, directors and consultants to purchase, and restricted common stock, restricted stock units, and other awards for, up to 2,000,000 shares of common stock and was later amended in 2016 to increase the maximum number of shares reserved for grant to 4,000,000. Generally, options become exercisable over a three-year period from the grant date and expire five years after the date of grant. As of June 30, 2021, and December 31, 2020, the Company had 2,471,659, and 424,425, respectively, remaining options available for grants. The Milestone Scientific Inc. 2020 Equity Compensation Plan, as amended and restated (the "2020 Plan"), provides for awards of restricted common, stock restricted stock units, and other awards for options to purchase, up to a maximum 4,000,000 shares of common stock and expires in June 2031. Options may be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market value of common stock on the date of grant. In general, options become exercisable over a three-year period from the grant date and expire five years after the date of grant. On April 8, 2021, as part of its Succession Plan going into effect on April 23, 2021, the Company announced that Leonard Osser, the Interim Chief Executive Officer, would be accepting the role of Vice Chairman of the Board of Directors. As part of accepting this role, he would be granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date of grant, vesting over the five-year period after he steps down as Chief Executive Officer of the Company or ten years from the date of grant, whichever shall end first. The options were issued pursuant to the 2020 Plan. Milestone Scientific recognizes compensation expense over the requisite service period and in the case of performance-based options over the period of the expected performance. For the six months ended June 30, 2021 and 2020, Milestone Scientific recognized approximately $286,00 and $48,000 of total employee compensation cost, respectively. As of June 30, 2021 there was approximately $3.5 million of total unrecognized compensation cost related to non- vested options. Milestone Scientific expects to recognize these costs over a weighted average period of 4.4 years. A summary of option activity for employees under the plans and changes during the six months ended June 30, 2021 and 2020 is presented below:
|  | Number of Options |  |  | Weighted Averaged Exercise Price $ |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Options Value $ |
Options outstanding January 1, 2021 |  |  | 1,953,443 |  |  |  | 1.88 |  |  |  | 3.09 |  |  |  | 476,964 |
Granted |  |  | 2,032,175 |  |  |  | 2.48 |  |  |  | - |  |  |  | - |
Exercised during 2021 |  |  | (435,558 | ) |  |  | 1.58 |  |  |  | - |  |  |  | - |
Forfeited or expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options outstanding June 30, 2021 |  |  | 3,550,060 |  |  |  | 2.26 |  |  |  | 7.00 |  |  |  | 188,018 |
Exercisable, June 30, 2021 |  |  | 745,092 |  |  |  | 1.93 |  |  |  | 2.41 |  |  |  | 124,701 |
|  | Number of Options |  |  | Weighted Averaged Exercise Price $ |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Options Value $ |
Options outstanding January 1, 2020 |  |  | 1,212,442 |  |  |  | 1.71 |  |  |  | 2.40 |  |  |  | - |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised during 2020 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  | 1,212,442 |  |  |  | 1.71 |  |  |  | 2.40 |  |  |  | - |
Exercisable, June 30, 2020 |  |  | 1,117,829 |  |  |  | 1.84 |  |  |  | 1.84 |  |  |  | - |
The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the six month period ended June 30, 2021 risk free interest rate of .19%-1.15% , Volatility of 69.1%-94% (which is based on the Company’s historical volatility over the expected term), expected term of 3-6.5 years, 0% dividend rate and closing price of the stock of $2.46-$3.79. A summary of option activity for non-employees under the plans and changes during the six months ended June 30, 2021 and 2020 is presented below:
|  | Number of Options |  |  | Weighted Averaged Exercise Price $ |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Options Value $ |
Options outstanding January 1, 2021 |  |  | 74,997 |  |  |  | 1.41 |  |  |  | 3.18 |  |  |  | 54,748 |
Granted |  |  | 16,666 |  |  |  | 4.30 |  |  |  |  |  |  |  |  |
Exercised during 2021 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options outstanding June 30, 2021 |  |  | 91,663 |  |  |  | 1.69 |  |  |  | 2.87 |  |  |  | 77664 |
Exercisable, June 30, 2021 |  |  | 52,769 |  |  |  | 1.68 |  |  |  | 2.12 |  |  |  | 50,658 |
|  | Number of Options |  |  | Weighted Averaged Exercise Price $ |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Options Value $ |
Options outstanding January 1, 2020 |  |  | 49,998 |  |  |  | 1.87 |  |  |  | 2.94 |  |  |  | - |
Granted |  |  | 8,333 |  |  |  | 1.65 |  |  |  |  |  |  |  | - |
Exercised during 2020 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options outstanding June 30, 2020 |  |  | 58,331 |  |  |  | 1.87 |  |  |  | 2.94 |  |  |  |  |
Exercisable, June 30, 2020 |  |  | 41,663 |  |  |  | 1.71 |  |  |  | 2.03 |  |  |  | 84,579 |
The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the three and six months ended June 30, 2021, Milestone Scientific recognized approximately $4,800 and $15,000 expense related to non-employee options, respectively. For the six months ended June 30, 2020, Milestone Scientific recognized approximately $7,000 expense related to non-employee options, respectively. The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the six month ended June 30, 2021, risk free interest rate of 0.3 %, Volatility of 86.97% to 94.05%, expected term of 5 years, 0% dividend rate and closing price of the stock of $3.57 to $4.30. The information below summarizes the restricted stock activity for the six months ended June 30, 2021:
Restricted Stock Awards |  | Shares |  |  | Weighted Average Grant-Date Fair Value per Award |
Non-vested as December 31, 2020 |  |  | - |  |  | $ | - |
Granted |  |  | 79,365 |  |  |  | 2.52 |
Vested |  |  | - |  |  |  | - |
Non-vested as June 30, 2021 |  |  | 79,365 |  |  | $ | 2.52 |
For the three and six months ended June 30, 2021, stock compensation expense for restricted stock was $20,833.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration